Litigation Details for Mary Jane Jasin v. Vivus, Inc. (N.D. Cal. 2014)
✉ Email this page to a colleague
Mary Jane Jasin v. Vivus, Inc. (N.D. Cal. 2014)
Docket | ⤷ Try a Trial | Date Filed | 2014-07-18 |
Court | District Court, N.D. California | Date Terminated | 2016-04-19 |
Cause | 15:78m(a) Securities Exchange Act | Assigned To | Beth Labson Freeman |
Jury Demand | Plaintiff | Referred To | Howard R. Lloyd |
Patents | 10,086,005; 6,071,537 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Mary Jane Jasin v. Vivus, Inc.
Biologic Drugs cited in Mary Jane Jasin v. Vivus, Inc.
Details for Mary Jane Jasin v. Vivus, Inc. (N.D. Cal. 2014)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2014-07-18 | 1 | 10.84 6,981,000.00 5 10.84 113 11/8/20125 10.85 5 10.86 5 10.16 5 10,24 6,357,900.00_ $ 10.24 114 11/7/20125…Vivus patent was vulnerable to a patent challenge given the existence of an earlier filed patent and other… to disclose that: a. Vivus’s patent for stinia was at risk of patent infringement, freedom-to-operate… long enough, Tain stated: “Well the patent, those are the patent laws goes out to 2020. The company, …holds a patent on topiramate, an ingredient in stmia, for the treatment of obesity (the “Shank Patent”), which | External link to document | |
2015-06-18 | 31 | 9 obesity,” and the “Shank Patent,” U.S. Patent No. 6,071,537, which was held by Johnson & … 7 1999 patent filed by Dr. Susan McElroy, the “McElroy Patent,” U.S. Patent No. 6,323,236, … 6 other patents which they contend posed risks to the Najarian Patent: an earlier filed February…an August 25, 2014 transfer of the patent to Vivus, which patented topiramate alone … all related patent applications, 16 or the Patents, were transferred | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |